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Abstract
Background: Gambling and tobacco smoking are highly comorbid among North American adults. However, there
is a paucity of treatment options that are integrated (i.e. targeting both gambling and tobacco smoking
simultaneously), accessible, and evidence based.
Methods: The aim of this two-arm open-label randomized controlled trial is to examine the effectiveness of an
online, self-guided integrated treatment for problem gambling and tobacco smoking. A target sample of 214
participants will be recruited and be randomized into either an 8-week integrated or gambling only control
condition. Both conditions will consist of seven online modules following cognitive behavioural therapy and
motivational interviewing principles. Our three primary outcomes are (1) the number of days gambled, (2) money
spent on gambling activities, and (3) time spent in gambling activities. Secondary outcomes include gambling
disorder symptoms, cigarette use, and nicotine dependence symptoms. Assessments will be completed at baseline,
at completion (i.e. 8 weeks from baseline), and at follow-up (i.e. 24 weeks from baseline). Generalized linear mixed
modelling will be used to evaluate our primary and secondary outcomes. We expect that participants receiving
online integrated treatment will show larger reductions in gambling relative to those receiving a control gambling
only intervention. We further hypothesize that reductions in smoking will mediate these group differences.
Discussion: The rates of problem gambling and tobacco smoking are high in North America; yet, the treatment
options for both are limited, with no integrated treatments available. If supported, our pilot study will be a cost-
effective and accessible way to improve treatments for co-occurring problem gambling and tobacco use.
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Problem gambling [1, 2] and tobacco smoking [3, 4] are
highly comorbid [5, 6] in North America. Indeed, studies
show that tobacco dependence is the most common
comorbid disorder among problem gamblers, with
prevalence rates ranging from 41 to 60% [7–11]. Accord-
ing to the World Health Organization, tobacco use kills
up to 50% of its users—translating into nearly six million
deaths annually [12]. Tobacco use is also linked to
several chronic health conditions, including cancers, re-
spiratory problems, and cardiovascular diseases [12].
Given their high rates of smoking (relative to the general
population) [7–9], problem gamblers are thus dispropor-
tionately affected by the increased morbidity and mortal-
ity from tobacco use. Moreover, research to date shows
that co-occurring tobacco use compounds gambling-
related harms. Problem gamblers who smoke have more
severe gambling pathology [13], experience stronger
gambling urges [14], are more likely to have other men-
tal disorders [13], tend to bet larger sums of money and
spend more time in gambling activities [15], and have
greater financial problems [16]. Based on this, it has
been suggested that daily smoking, a central trigger for
gambling and related cravings, may undermine the treat-
ment of problem gambling [5]. Accordingly, a priority
needs to be placed on integrating the treatment of to-
bacco smoking into evidence-based interventions for
problem gambling. In this study, we aim to design and
test a novel online pilot study for comorbid problem
gambling and tobacco use.
The proposed open-label pilot intervention will draw
on strategies from cognitive behavioural therapy (CBT)
and motivational interviewing (MI)—both evidence-
based psychotherapies for problem gambling [17–19]
and smoking [20, 21]. A main strength is that this pilot
study will be integrated—meaning that it will use treat-
ments for both problem gambling and tobacco smoking
to target the functional relations between each behaviour
within the same treatment. This is in contrast to limited
traditional approaches, which include treating these
problems either one at a time or simultaneously by two
different professionals. The online platform also offers
key advantages relative to in-person modalities. First,
some provinces across Canada (e.g. Manitoba and
Saskatchewan) and states in the USA have significant
rural spread, meaning that communities are dispersed
throughout the area with little access to major cities.
This poses huge challenges for providing equal access to
mental health care services for all citizens. In fact, statis-
tics suggest that people living in remote communities
struggle most with addictive behaviours and mental
health issues but have limited access to treatment facil-
ities [22]. Thus, we will be better able to reach these
people with an online treatment. Second, many problem
gamblers do not seek traditional forms of treatment due
to stigma [23]. Problem gamblers may be more willing
to try online interventions due to anonymity and re-
duced shame [24]. This integrated intervention has the
potential to have positive impacts on the health of adult
North Americans who struggle with problem gambling
and tobacco use.
Evidence for the association between problem gambling
and tobacco smoking
Based on the epidemiological literature showing very
high prevalence rates of tobacco smoking among prob-
lem gamblers, researchers have begun to examine the
potential reasons for this association. While we still do
not know the exact mechanisms underlying the problem
gambling-tobacco use comorbidity, neurobiological stud-
ies suggest that both addictive behaviours are mediated
by similar reward circuits in the brain [5]. Specifically,
neurobiological work shows that drugs of abuse, includ-
ing nicotine, increase transmission of dopamine in
mesocorticolimbic regions [25, 26]. This effect is thought
to underlie the reinforcing properties of substance use.
Similarly, data suggest that gambling is also associated
with increased activity in dopaminergic-rich areas of the
mesocorticolimbic circuit. For example, in a double-
blinded laboratory study [27], it was shown that admin-
istration of amphetamine (a potent dopamine agonist or
releaser) increased motivation to gamble among individ-
uals with gambling problems. Taken together, tobacco
use and problem gambling appear to act on similar
neural pathways that underlie addictive, reward-driven
behaviours.
Functionally, research shows that nicotine may enhance
or augment the reinforcing value of other addictive behav-
iours [5, 28]. Nicotine has been shown to lead to increased
self-administration of alcohol in male smokers [29], in-
creased cravings in cocaine-dependent smokers [30], and
increased self-administration of methadone in opioid-
dependent smokers [31]. Compared to alcohol and other
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drugs, very little neurobiological work has been done to
show direct functional effects of nicotine on the reinfor-
cing qualities of gambling. Indirect evidence for nicotine’s
effects on gambling behaviour, however, comes from stud-
ies examining the impact of monetary reward on dopa-
minergic transmission in the brain. Overall, this work
shows that when individuals receive uncertain or variable
monetary rewards (i.e. those that cannot be predicted by
any regularity), they show increased dopaminergic activity
in the very same regions associated with tobacco use [32,
33]. In comparison, when monetary rewards are certain or
predictable, there is no increased dopaminergic transmis-
sion in these brain regions. Given that uncertain or vari-
able reinforcement is a hallmark of gambling, one could
predict that co-occurring tobacco use could promote or
reinforce gambling and gambling-seeking behaviours over
time (via nicotine’s effects on dopaminergic brain regions
in the mesocorticolimbic pathway).
Complementing neurobiological studies, behavioural
research demonstrates that nicotine may alter reward-
related cognitive processes that increase risk for problem
gambling [5]. To illustrate, nicotine may enhance the sa-
lience of short-term rewards from gambling, while
detracting focus from gambling’s longer-term negative
outcomes. This notion is supported by work showing
that heavy smokers engage in risky decision-making on
the Iowa Gambling Task, with response patterns show-
ing a preference for short-term gains at the expense of
long-term losses [34]. Heavy smokers also show steeper
discounting of future rewards relative to non-smokers
[35], suggesting that nicotine may reinforce impulsive
behaviour—like gambling—where the goal is the imme-
diate reward. It is possible that tobacco smoking (via
nicotine’s effects on learning and reward systems in the
brain) strengthens problem gambling, making this be-
haviour difficult to extinguish especially when repeatedly
paired with cigarette use. This may account for the in-
creased clinical severity in heavy smoking (relative to
non-smoking) problem gamblers. Moreover, some stud-
ies demonstrate that nicotine may enhance cognitive
processes, like attention and executive control [36].
These momentary effects may be highly desirable to
problem gamblers, as they may experience a greater abil-
ity to focus and shift attention during gambling episodes
(after smoking).
Finally, the literature on cross-cue reactivity shows
that tobacco use and problem gambling may become
powerful reciprocal triggers for each behaviour [37].
That is, through repeated co-occurrence, stimuli associ-
ated with smoking are believed to become conditioned
stimuli for gambling and vice versa. For example, over
time, smoking cues can come to elicit strong urges to
gamble, and conversely, gambling cues can come to pro-
mote cravings for tobacco use. While this is a relatively
understudied research area, recent data show that gam-
blers who smoke had greater cross-cue reactivity (com-
pared to gambling and smoking only control groups)
[37]. Results suggested that smoking gamblers had
increased physiological arousal and greater subjective
desire to smoke, irrespective of whether cues were
smoking- or gambling-related [37]. Accordingly, if to-
bacco use potentiates gambling—and vice versa—then it
would be very challenging for a person to reduce either
behaviour in isolation.
Existing evidence-based treatments for problem
gambling
Existing evidence-based treatment protocols for problem
gambling generally combine strategies from two main
psychological intervention frameworks: CBT and MI [17,
38]. CBT is a structured and goal-oriented treatment,
where individuals acquire skills to reduce problem gam-
bling through modifying thoughts and behaviours in re-
sponse to internal (e.g. negative emotions) and external
(e.g. gambling cues) triggers. During CBT, individuals
with gambling problems strengthen coping skills by
completing various exercises both in-session and at
home between sessions. Complementing CBT, MI
strategies are used in gambling treatment to elicit and
motivate positive change. MI is a patient-centred and
collaborative approach, where the goal is to help patients
resolve ambivalence about change and get them to move
in a direction that is consistent with personal values. MI
is typically a prelude to CBT, but also a style that a ther-
apist can return to if barriers are encountered during
CBT. The weight of the evidence demonstrates that the
combination of CBT and MI has synergistic beneficial
effects on gambling and smoking behaviours during
treatment [17–19, 21, 38]. By increasing motivation for
change using MI, individuals with problem gambling
may be more willing to engage in the effortful activities
of CBT (e.g. homework), which in turn, are essential for
building better coping skills. Integrated MI may also
help to clarify a problem gambler’s core values in CBT
by creating a discrepancy between current and desired
behaviour. Thus, from a theoretical perspective, CBT
and MI naturally complement each other in the treat-
ment of problem gambling. Supporting this, a recent
meta-analysis showed that CBT/MI treatments reduce
problem gambling symptoms with medium effect sizes
[17], and online CBT treatments reduce problem gam-
bling amount, frequency, and urges [39].
Despite CBT/MI’s effectiveness for reducing gambling,
there are notable problems with existing approaches.
First and foremost, while CBT/MI approaches have been
shown to be helpful, effect sizes on short- and long-term
gambling outcomes are modest [17]. This suggests that
there is a great deal of room to improve interventions
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for gambling. Second, dropout rates in problem gam-
bling treatment studies are substantial. Specifically, it
has been estimated that 14 to 50% of individuals with
problem gambling drop out of active treatment, with the
average being about 30% across studies [40, 41]. This
suggests that a large portion of treatment-seeking indi-
viduals with problem gambling do not complete this effi-
cacious psychological intervention. Third, individuals
with problem gambling show marked problems with
treatment adherence, as evidenced by poor homework
completion and low session attendance [42]. Addition-
ally, comprehensive self-guided treatments are shown to
be as effective as face-to-face treatments for problem
gambling [43]. Adherence may be especially poor among
the 50 to 70% [44] of problem gamblers with co-
occurring substance use problems. In turn, poor treat-
ment adherence predicts poor responses to intervention
[42, 45]. Finally, similar to people with tobacco use dis-
orders [46], relapse rates among treated problem gam-
blers remain very high [47]. As a whole, these issues
suggest that we need to find effective ways to augment
CBT/MI to improve clinical outcomes for problem
gambling.
Based on the neurobiological and behavioural litera-
ture discussed above, it is highly possible that comorbid
tobacco use is a factor that helps to maintain and
reinforce problem gambling behaviours—even after
treatment engagement. Despite their best efforts in treat-
ment, individuals with problem gambling who smoke
(versus those who do not smoke) may have marked diffi-
culty controlling gambling urges, forming new non-
gambling-related associations, and shifting focus to
adaptive future (relative to often maladaptive and imme-
diate) goals in therapy [5, 35, 36]. These difficulties may
contribute to commonly observed poor treatment en-
gagement and completion and the modest success of
problem gambling treatment among individuals with
problem gambling. Unaddressed daily tobacco use may
also be a critical factor in high rates of relapse among
treated problem gamblers. Very few studies have ex-
plored smoking status and its relationship to gambling-
related treatment outcomes [48]. As noted earlier,
tobacco-related cues are powerful conditioned stimuli
that elicit strong cravings among problem gamblers [37].
It follows that even after treatment, individuals with
problem gambling who continue to smoke will have to
fight against strong urges resulting from their increased
cross-cue sensitivity. Thus, a key augmentation to CBT/
MI treatments for problem gambling would be to in-
clude content to address co-occurring tobacco use.
Integrated treatment
Research on integrated addiction treatment is relatively
new. This is surprising, given that it is common for
individuals to present with more than one addictive be-
haviour [49]. Polysubstance use is associated with greater
clinical severity and poorer treatment outcomes [50].
Further, poor treatment outcomes have also been ob-
served for gamblers with substance abuse treatment his-
tory compared to gamblers without substance abuse
treatment history [51]. Traditional methods for treating
co-occurring addiction/mental disorders are sequential
and parallel intervention [49]. During a sequential ap-
proach, clinicians treat the addiction/disorder viewed as
“primary” first, followed by the treatment of the comor-
bid condition. For example, a person with co-occurring
alcohol misuse and problem gambling would likely not
be able to work on reducing gambling until they achieve
some notable period of abstinence from drinking. Thus,
in the sequential model, treatment is provided for one
disorder at a time—with the more acute disorder (e.g. al-
cohol misuse) taking first priority. The sequential model
of intervention has been (and still is) the most widely
used approach to treating disorder comorbidities. In
contrast, the parallel model involves treating co-
occurring problems separately by two distinct profes-
sionals and/or clinical teams, each with expertise in one
of the two problems [52]. An example of this approach
would be a person seeing a family doctor for manage-
ment of smoking, while working with a psychologist to
reduce gambling. Therefore, in the parallel model, an in-
dividual receives support for both issues simultaneously,
but from distinct professionals.
Although still widely used, sequential and parallel ap-
proaches are limited as intervention models for comor-
bid addictive behaviours [52]. A sequential approach
may be necessary in crisis situations, such as when a
person needs hospitalization for alcohol-related seizures.
However, in the absence of an emergency warranting
the immediate stabilization of one disorder over the
other, sequential treatment may impede the treatment of
both addictive behaviours [52]. Sequential treatment
does not consider the interconnectedness of addictive
behaviours. To illustrate, a person would likely find it
very challenging to reduce gambling if their smoking (a
main trigger for gambling) remains untouched in treat-
ment. In turn, this person’s smoking (perhaps as a cop-
ing mechanism) would likely be worsened by repeated
failed attempts to control gambling. In such a scenario,
it would be difficult for this person to make major im-
provements on either problem. Moreover, in a parallel
treatment model, there is often little communication be-
tween the professionals independently treating each
problem [52]. This is problematic because professionals
often have different case conceptualizations and treat-
ment recommendations. For example, a physician may
emphasize the usefulness of medication over psychother-
apy, whereas the reverse may be true for a psychologist.
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Hence, it is very common for a person to get conflicting
advice and feedback in a parallel treatment approach
[52]. Furthermore, it is up to the patient to “integrate”
distinct treatment approaches, which is likely difficult
due to high rates of cognitive impairment among those
with problem gambling [53]. Finally, another potential
problem for the client is the demands of attending two
separate treatments (i.e. time, money). The limitations of
a parallel approach may lead to adverse patient out-
comes, such as frustration, continued mental health
challenges, and in the most extreme case, discontinu-
ation of treatment. Overall, attesting to these limitations,
the literature shows that sequential and parallel ap-
proaches result in poor treatment outcomes in those
struggling with addictive behaviours [52].
The main advantage to an integrated treatment frame-
work is that it recognizes common etiological mecha-
nisms underlying co-occurring addictive behaviours.
Hence, from a common mechanism or “transdisease” ap-
proach [54], one can design a treatment that helps indi-
viduals achieve notable improvements on more than one
addictive disorder at a time. We posit that combined
CBT/MI represents a general framework to target co-
occurring problem gambling and tobacco use. CBT/MI
therapies have been shown to be effective for smoking
cessation across many studies [55], and these approaches
are very similar in content to those used for problem
gambling. Overall, CBT/MI therapies help people ac-
quire coping skills to deal with addictive behaviours
broadly, including building motivation, improving un-
derstanding of triggers (i.e. learning how smoking is a
trigger for gambling), avoiding high-risk situations, de-
veloping balanced ways of thinking, and creating well-
informed relapse prevention plans. Numerous articles
support the efficacy of these CBT/MI strategies for the
treatment of problem gambling, tobacco use, and addict-
ive behaviours more broadly [17, 55]. In the gambling
literature, approaches aimed at targeting both problem
gambling and alcohol use [56] or mental health difficul-
ties [57] were shown to have no significant difference in
outcomes between the separate and integrated treatment
interventions; however, a limitation to both trials relied
on a more sequential approach to treatment and lacked
a stronger integrated component. Given CBT/MI’s em-
phasis on general coping skill development, we posit that
it is an ideal framework for an integrated intervention
for co-occurring problem gambling and tobacco use.
The current study
This open-label pilot study will address a notable gap in
the literature on problem gambling treatment. It has
been known for a long time that a high proportion of
gamblers smoke cigarettes [7, 8] and that daily smoking
compounds gambling severity [13–16]. However, very
little work has been done to systematically address the
problem of smoking in treatment for problem gambling.
In fact, to our knowledge, no existing treatment proto-
cols have integrated content to help problem gamblers
reduce smoking. Using a randomized controlled trial
(RCT), we will be the first to design, implement, and test
a novel online integrated treatment for problem gam-
bling and comorbid smoking. Relative to traditional
face-to-face approaches, there are distinct advantages to
an online delivery of integrated treatment in North
American. First, online interventions would be able to
reach adults from rural and Northern communities
across North America. We know from health statistics
that the highest rates of addictive behaviours and
addiction-related deaths exist in these communities [58,
59]. Second, adults with gambling issues may be more
willing to engage in a self-help online intervention (rela-
tive to in person). This is because an online modality
may be associated with reduced shame and stigma—
which are known, persistent barriers to seeking treat-
ment among problem gamblers [24]. Finally, online in-
terventions could significantly reduce the burden on
mental health care systems in North America. More
people with gambling problems would be helped for
much less cost relative to hospital treatments. Data show
that cost-effective, online psychosocial interventions re-
duce problem gambling [60] and tobacco use [61], separ-
ately. Therefore, the literature supports the online
modality as a means to deliver our proposed integrated
pilot study.
Objectives
Informed by the literature, our primary aim will be to
examine if integrating treatment of comorbid tobacco
smoking improves gambling outcomes among North
Americans with problem gambling relative to a focus on
problem gambling alone. Our second aim will be to test
if reduced smoking explains (or mediates) the beneficial
effects of the integrated treatment on gambling. We ex-
pect that participants receiving online integrated treat-
ment will show larger reductions in gambling relative to
those receiving a control gambling only intervention.
We further hypothesize that reductions in smoking will
mediate these group differences.
Methods/design
Design
This open-label pilot project will consist of a two-arm
RCT (Clinicaltrials.gov ID NCT03614884; see Figs. 1
and 2 for an overview). Dr. Keough and his research
team will collect the data in Canada and the USA. Par-
ticipants will be randomly assigned into one of two con-
ditions. In the experimental condition, participants will
receive an 8-week online integrated intervention for
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problem gambling and smoking. In the control condi-
tion, participants will receive a similar 8-week online
intervention for problem gambling without treatment
content to address smoking. Online assessments will
occur before randomization (T0; baseline), at 8 weeks
since baseline (T1; treatment end), and at 24 weeks since
baseline (T2; follow-up; see Table 1). The timeline of
these assessments, including the longer-term follow-up,
is consistent with previous RCTs examining technology-
based interventions for problem gambling and those for
smoking cessation [62, 63]. Participants will be compen-
sated based on the following schedule: $20 per assess-
ment, a bonus of $20 for completing all three
assessments, and $20 for completing at least five of the
treatment modules (max compensation per participant =
$100). For ethical reasons, participants will be compen-
sated in the form of gift cards to Amazon.ca. This RCT
is registered with ClinicalTrials.gov for transparency and
to avoid publication bias. Prior to the initiation of the
study, we obtained ethical approval from the Research
Ethics Board (REB) at the University of Manitoba
(#P2018:088 HS22037) and York University (ES2020-
006).
Recruitment
A target sample size of N = 300 will be recruited. Dr.
Keough’s research team will oversee online data recruit-
ment and collection. A variety of methods will be used
to recruit potential participants. Dr. Keough will recruit
from cities across Canada and the USA using online ads
(e.g. Google Ads, Craigslist, Kijiji, and local news web-
sites), local avenues (i.e. newspapers), and governmental
organizations (i.e. Manitoba Liquor & Lotteries). Given
the high rates of problem gambling and tobacco smok-
ing in Canada and the USA [7–9, 12], it should be feas-
ible to recruit the required sample size.
Another very important issue will be to recruit a suffi-
cient number of women to be able to examine gender
Fig. 1 Schematic of the randomized controlled trial methodology
Bilevicius et al. Trials          (2020) 21:937 Page 6 of 16
differences in treatment effects. Based on the literature,
about one-third of individuals with problem gambling
from the community will be women [64]. We will make
every effort to ensure that at least one-third of our final
sample is comprised of women, although we will aim for
a higher percentage during the recruitment process. In-
clusive recruitment will ensure that both genders equally
contribute to and benefit from the intervention. This is
very important, since data show that women are drastic-
ally underrepresented in gambling treatment settings. To
illustrate, only 2–7% of those who attend Gambler’s
Anonymous are women [65]. We aim to greatly improve
these numbers for our trial.
Inclusion criteria
Our main target demographic will be adults with moder-
ate levels of gambling problems who identify as daily
smokers. Inclusion criteria will include (1) ages 19+, (2)
problem gambling status based on reporting a score of
> 3 on the Problem Gambling Severity Index (PGSI), (3)
reporting current daily smoking, (4) fluency in English,
and (5) have weekly Internet access.
Fig. 2 Schedule of enrolment, interventions, and assessments. t0, baseline (at outset of intervention); t1, 8 weeks (at completion of the
intervention); t2, 24 weeks (at 4 months following completion of the intervention); AUDIT, Alcohol Use Disorder Identification Test; DAST-10, Drug
Abuse Screening Test-10; TLFB, Timeline Followback; PGSI, Problem Gambling Severity Index; Fagerstrom test, Fagerstrom test of nicotine
dependence; G-SAS, Gambling Symptom Assessment Scale; P4, P4 suicide screener; withdrawal scale, Hughes-Hatsukami withdrawal scale
Table 1 Schedule of assessments for measures
Self-report measures Baseline (T0) 8 weeks (T1) 24 weeks (T2)
1. Demographics (e.g. age, gender, treatment history, psychiatric/medical history) X
2. Alcohol Use Disorders Identification Test (AUDIT) X
3. Drug Abuse Screening Test-10 (DAST-10) X
4. Timeline Followback (TLFB) for gambling, smoking, alcohol, and substance use X X X
5. Gambling Symptom Assessment Scale (G-SAS) X X X
6. Problem Gambling Severity Index (PGSI) X X X
7. Fagerstrom test for nicotine dependence X X X
8. P4 suicide screener X X X
9. Withdrawal scale X X X
10. NIDA-ASSIST X X X
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Exclusion criteria
Exclusion criteria will include (1) self-reported current
engagement in other psychosocial treatments for prob-
lem gambling and/or smoking, (2) elevated suicidality
(scoring greater than “minimal risk” on the P4 suicide
screener) [66], (3) past-90-day psychosis or mania, and
(4) presence of a severe substance use disorder (SUD).
SUD severity will be determined based on established
cut-offs on widely used and validated screening mea-
sures for alcohol and other drug use. For alcohol, indi-
viduals with a score of > 20 on the Alcohol Use Disorder
Identification Test (AUDIT) [67] will be excluded from
the study. For other substance use, individuals with a
score of > 5 on the Drug Abuse Screening Test-10
(DAST-10) [68] will be excluded. The rationale for ex-
cluding those with severe SUDs is based on the large lit-
erature showing that these individuals need intensive
residential treatments (with corresponding medical
supervision) [69] and hence would not benefit from self-
guided online interventions, such as the one to be pro-
vided in the current study. We will provide a list of local
addiction and financial resources for those with severe
AUD and SUD symptoms.
Sample-size justification and statistical plan
A meta-analysis showed that CBT/MI (relative to con-
trol) treatments have medium effects on gambling [17].
However, we will be comparing two active treatments,
which may result in smaller effect sizes. Accordingly, we
used G*Power to calculate the sample size needed to de-
tect a small effect size for our primary outcome. We
used a 2 (between subjects; treatment condition) by 3
(within subjects; time) mixed design. Assuming a power
rate of .80, an α of .05, and a correlation of .50 between
repeated measures, the required sample size to detect a
small effect size is N = 164. Given an average attrition
rate of 30% in gambling treatment studies [17], our final
adjusted sample size is N = 214. Generalized mixed mod-
elling will be used to evaluate the main hypothesis that
integrated online treatment will result in the larger re-
ductions in gambling than the gambling only treatment.
Primary and secondary outcomes will be tested sequen-
tially. We will include all randomized participants in
analyses (i.e. intent-to-treat). Missing data will be
accounted for using full information maximum likeli-
hood estimation. We will include some covariates in our
models if needed. Relevant covariates may include his-
tory of psychological treatment, age, gender, and base-
line severity of gaming and smoking behaviours. Of
particular relevance, we expect variability in adherence
to NRT; therefore, we will explore whether NRT use
(e.g., # of days patch was used during treatment) affects
primary/secondary treatment outcomes.
Primary outcomes
Gambling behaviour There will be three primary out-
comes to capture intervention-related change in gam-
bling behaviour. Specifically, participants will be asked
about their past-30-day gambling frequency (# of days
gambled), money spent on gambling activities (in dol-
lars), and time spent engaged in gambling activities (# of
minutes). These primary indices were selected because
they are common outcomes in RCT studies examining
CBT/MI approaches to the treatment of problem gam-
bling [17, 70]. The Timeline Followback (TLFB) proced-
ure will be used to collect data for the primary outcomes
[71]. Anchoring gambling to specific calendar dates
helps to improve the accuracy of self-reported involve-
ment in these activities. The TLFB procedure has also
been shown to produce relatively accurate estimates of
addictive behaviour involvement when participants are
ensured anonymity [72]. Furthermore, recent data shows
that a self-report web-delivered version of the TLFB (like
the one to be used in this study) produces reliable and
valid estimates of addictive behaviours [73].
Secondary outcomes
Gambling Symptom Assessment Scale (G-SAS) The
G-SAS is a 12-item self-report questionnaire that was
designed specifically to capture change in gambling
symptoms following treatment [74]. The G-SAS has a
unidimensional structure, and psychometric work shows
that G-SAS total scores have good reliability and good
convergent validity with clinician-rated measures of
gambling symptom change during treatment, such as the
Yale-Brown Obsessive Compulsive Scale modified for
Pathological Gambling [74]. The main advantage of
using the G-SAS as a secondary measure of gambling
symptom change is that it includes several questions
about gambling urges. While urges are expected to de-
crease with intervention, existing widely used measures
(e.g. Problem Gambling Severity Index [PGSI]) do not
include items to assess urge change during treatment.
The G-SAS also includes items to assess changes in
gambling harms during treatment (e.g. reductions in
emotional distress). In the present study, the total G-
SAS score will serve as a secondary measure of gambling
change after intervention.
Problem Gambling Severity Index (PGSI) The PGSI is
the most widely used self-report measure of gambling
harms in the literature [75]. The PGSI contains nine
items that assess a broad array of problems experienced
by individuals who engage in problem gambling (e.g.
guilt, financial problems etc.). Previous work supports
the PGSI’s good reliability and validity [75]. The total
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PGSI score will be used in this study to capture changes
in gambling harms following the intervention.
Cigarette use The TLFB procedure will also be used to
collect information about past-30-day cigarette use. A
sum score will be used to reflect total smoking behav-
iour at each assessment. This secondary outcome will be
used to capture intervention-related change in smoking
behaviour. As noted above for gambling, recent data
show that a self-report web-delivered TLFB provides
valid estimates of cigarette use [73]. In addition to col-
lecting information on cigarette use, we will also use the
TLFB procedure to code for episodes of co-occurring
gambling and smoking. That is, participants will be
asked to denote the days in which they smoked while
gambling (e.g. leaving a bar with VLTs momentarily to
smoke, then resume playing). This variable may be used
for secondary analyses, depending on the variability in
the data.
Nicotine dependence symptoms The Fagerstrom Test
of Nicotine Dependence is a six-item self-report measure
that captures the severity of nicotine dependence symp-
toms [76]. The Fagerstrom total score will be calculated
at each time point and will be used to assess
intervention-related changes in nicotine dependence
symptoms. Previous work shows that the Fagerstrom has
good reliability and validity [76] and is sensitive to
treatment-induced change [77].
Withdrawal scale The Hughes-Hatsukami Withdrawal
Scale [78] is a 13-item self-report measure that assesses
symptoms of tobacco withdrawal. Previous work shows
that the Hughes-Hatsukami Withdrawal Scale has good
reliability and validity [78].
NIDA-ASSIST The National Institute on Drug Abuse—
Alcohol, Smoking and Substance Involvement Screening
Test [NIDA-ASSIST] [79] is a 10-item scale that assesses
the level of risk associated with different substance in-
volvement. A total score will be computed for drug use.
P4 suicide screener The P4 suicide screener [66] is 4-
item self-report measure that evaluates an individual’s
level of suicide risk. It assesses past suicide attempts,
suicide plan, probability of completion, and preventa-
tive factors. Individuals who endorse one or more of
the aforementioned criteria are deemed to be greater
than minimal risk and will be excluded from the
intervention. The P4 suicide screener has good reli-
ability and validity [66].
Informed consent and randomization
Participants will first read the study rationale on the
intervention website and then will be told the following
during informed consent: (1) the inclusion/exclusion cri-
teria, (2) the potential risks/benefits, (3) the safety ar-
rangements during and after the study, (4) the
programme is self-guided, (5) the circumstances under
which they should contact a medical professional from
an emergency list that will be accessible at all times via
the menu item “Help Me” on the intervention website,
and (6) participation is voluntary. Participants endorsing
significant suicide ideation and/or plans will be told to
visit a hospital for support. For ethical reasons, individ-
uals with clinically elevated SUD/AUD symptoms (i.e.
those who score above the cut-offs on our screening
tools) will be given access to the integrated intervention
and will be given the contact information for mental
health professionals in their area. However, they will be
excluded from the study. Following informed consent,
participants will register on the intervention website and
complete baseline assessments to determine eligibility
using inclusion/exclusion criteria. After completion of
the baseline measures, a computer programme will be
used to randomize eligible participants to the treatment
conditions. Once participants are randomized, an inter-
vention support person will be aware to their respective
conditions (i.e. unblinded). Additionally, participants will
also be aware of their assigned condition. It would be
difficult to achieve blindness as both participants and
intervention support personnel will be aware of the con-
dition through the delivery of NRT.
Prior to starting the pilot study, an intervention sup-
port person will contact all participants via phone or
email to confirm eligibility and willingness to participate.
Contact information (i.e. phone number and chosen
email) will be collected via the intervention website and
is stored separately from participant data. It is important
to note that the intervention support person does not
have any formal training in clinical psychological treat-
ment to ensure that participants were not inadvertently
receiving psychotherapy. The role of the intervention
support person is to strictly answer participant-initiated
questions about the website and pilot study.
Integrated treatment (experimental condition)
Participants in this condition will have access to seven
treatment modules over 8 weeks (see Fig. 3 for the over-
view of the module interface). The specific gambling
content will be adapted from a self-help intervention de-
veloped by Dr. Hodgins (a co-investigator on the pro-
posed project; see Table 2 for module content for
integrated intervention). This intervention has been vali-
dated in several trials [38, 70] and has been successfully
adapted for online delivery [55, 80]. Smoking content
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will be adapted from existing evidence-based CBT/MI
protocols, including the most widely used best practice
guidelines from both Abrams et al. and Fiore and col-
leagues [55, 81]. One standard care guideline for smok-
ing cessation interventions is the combined use of
nicotine replacement therapy (NRT) and psychosocial
support (CBT/MI) [55, 81]. Accordingly, in the first
module, participants in the integrated treatment arm will
be provided with an extensive fact sheet on NRT use—
including the strong evidence supporting its use in con-
junction with psychosocial treatment for smoking cessa-
tion. Participants will be (1) encouraged to use NRT
patches for the 8 weeks of active treatment, (2) advised
that NRT patches are available over the counter at any
local pharmacy, (3) provided with NRT patches for the
duration of treatment, and (4) advised to consult with
their family physician should they have any medical
questions related to NRT patches. As noted in best prac-
tice guidelines [81], the dosage schedule of NRT patches
will be the following: 24 mg for 4 weeks then 14 mg for
2 weeks and finally 7 mg for the remaining 2 weeks.
NRT will be mailed out to each participant at the outset
of their registration to ensure that they have it for the
duration of the pilot study. NRT usage will be tracked
weekly during the active intervention and also at each
follow-up assessment.
The psychosocial integrated treatment content is fully
summarized in Table 2. As noted earlier, all components
of this pilot study come from well-established CBT/MI
protocols for problem gambling and smoking cessation
[17, 55]. Integrated content will allow participants to
understand the links between gambling and smoking;
identify and set goals related to gambling and smoking,
as well as make goals for increasing involvement in
pleasurable and positive activities; learn to identify and
plan for “high risk” situations related to smoking and
gambling; develop strategies to cope with gambling and
smoking urges; learn to challenge and/or alter thoughts
that promote gambling and smoking; and learn how to
prevent relapse of each behaviour. Participants will have
immediate access to all modules, and it will be recom-
mended that they work through the modules sequen-
tially. However, any order is possible. An adult might,
for example, jump ahead to a module on craving, if they
are having strong urges to smoke in a given week. Par-
ticipants will be encouraged to complete the modules as
many times as needed, and their progress will be visible
on a digital progress bar. If participants leave a module
and revisit it later, they will restart where they left
off. Participants will be asked to track both gambling
and smoking behaviours each week. On the “dash-
board” intervention page, participants will be able to
see a graph depicting their individualized treatment
progress for their gambling and smoking behaviour.
The website will automatically adapt for use on
smartphones and tablets.
Fig. 3 Main menu of intervention modules
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Gambling only treatment (control condition)
The control group will receive a similar 8-week online
intervention for gambling only. The gambling content
will be the same as in the experimental condition, but
there will be no treatment content about smoking and
no integrated content. The complete module content for
the gambling only (control) arm is summarized in
Table 3.
Discussion
Possible challenges and mitigation plan
Adherence to treatment
The literature shows that adherence to treatment tends
to be suboptimal in addictive behaviour intervention
studies, including both in-person and online modalities
[82]. To address this potential challenge, the proposed
intervention will have features aimed at improving ad-
herence, including automatic reminders to complete
modules and assessments. Inclusion of these strategies
within this pilot study was based on literature showing
that frequent automatic and specific feedback improves
adherence to self-guided behavioural change interven-
tions [83].
Recruitment
As noted in the methodology section, Dr. Keough and
his research team will make every effort to recruit adults
across North America. Our intent is to recruit using as
many different recruitment strategies as possible, such as
through Web-based advertisements (e.g. Google Ads,
Kijiji ads, Craigslist), local avenues (e.g. posting recruit-
ment flyers in public spaces), through social media (e.g.




M1: Introduction • Introduction to the intervention and website
• Psychoeducation about the links between gambling and cigarette smoking, including a rationale for working on both in
treatment together
• Motivational enhancement (i.e. identifying reasons for change, and pros and cons of gambling/not gambling, and
smoking/not smoking)
• Psychoeducational fact sheet on nicotine replacement therapy (NRT), including a strong recommendation for using NRT
during the intervention
• Self-monitoring gambling and smoking behaviours, including frequency of co-occurrence
M2: Goal setting • Determine personal goals related to gambling and smoking (i.e. abstinence versus harm reduction)
• Develop SMART (specific, measurable, achievable, realistic, and timely) goals for gambling and smoking reduction
M3: Risk situations • Resisting gambling in specific situations (e.g. situations involving negative emotions)
• Developing personal strategies to reduce/abstain from harmful gambling and to control access to money
• Introduce need for pleasurable activity scheduling (i.e. behavioural activation)
• SMART goal setting for pleasurable, low-risk, and healthy activities (e.g. activities that are incompatible with gambling and
smoking)
M4: Identifying triggers • Strategies for avoiding triggering situations related to smoking
• Identify strategies for refusing smoking and gambling
M5: Unhelpful thinking • Review common thinking errors related to gambling (or “gambling traps”) and smoking
• Psychoeducation about games of chance
• Identify how misperceptions about gambling odds impact one’s inner dialogue or thoughts
• Psychoeducation about thinking traps related to smoking
M6: Cravings • Psychoeducation about craving
• Introduce self-monitoring of craving
• New ways to effectively cope with cravings (e.g. distraction, urge surfing, and recalling the negative outcomes of
gambling)
• Identifying the similarities and differences between gambling and smoking cravings
M7: Dealing with slips • Define a “slip” versus a full-blown relapse
• Introduce ways to cope with slip in meeting gambling and smoking goals
• Introduce relapse prevention planning
• Create personalized relapse prevention plan
• Identify three coping strategies for preventing gambling and smoking
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Twitter, Facebook), and using community and university
organizations to promote the intervention. Recruitment
posters will also be posted at popular gambling locations
(e.g. restaurants and bars). This will help to increase re-
cruitment in each province. However, it is possible that
issues with suboptimal recruitment will occur. Recruit-
ment rates will be monitored on an ongoing basis (e.g. %
completing screening relative to % meeting criteria to
participate).
Attrition
Intervention studies show substantial variability in attri-
tion rates, depending on treatment orientation, clinical
severity, and so forth [17]. Generally, dropout rates are
high in populations with behavioural and substance use
addictions—ranging from 21 to 80% [84]. We are aware
of this possible influence on attrition. Regular contact
will be provided via automated emails and, if a partici-
pant prefers, phone to provide personalized support that
is not typical of online interventions. It has been shown
that automated and personalized support in self-guided
interventions can improve treatment adherence and re-
duce attrition [85]. This may reduce dropout. Finally, we
will offer participants the possibility to receive a person-
alized feedback report at the end of the study. This re-
port will contain information about their treatment
progress. The combined use of the strategies above will
help reduce the attrition rate.
Methods: monitoring
A formal data monitoring committee (DMC) was not in-
cluded in the present RCT due to budgetary reasons (i.e.
there was no dedicated funding to compensate inde-
pendent committee members). Instead, we opted to in-
clude co-investigators on this trial who have extensive
experience in conducting online treatment RCTs. This
study was also intended to be an open-label pilot inter-
vention, and the plan is for subsequent larger trials to




M1: Introduction • Introduction to the intervention and website
• Motivational enhancement (i.e. identifying reasons for change, and pros and cons of gambling and not gambling)
• Self-monitoring gambling behaviours
M2: Goal setting • Determine personal goals related to gambling (i.e. abstinence versus harm reduction)
• Develop SMART (specific, measurable, achievable, realistic, and timely) goals for gambling reduction
M3: Risk situations • Resisting gambling in specific situations (e.g. situations involving negative emotions)
• Developing personal strategies to reduce/abstain from harmful gambling and to control access to money
• Introduce need for pleasurable activity scheduling (i.e. behavioural activation)
• SMART goal setting for pleasurable, low-risk, and healthy activities (e.g. activities that are incompatible with gambling)
M4: Cravings • Psychoeducation about craving
• Introduce self-monitoring of craving
• New ways to effectively cope with cravings (e.g. distraction, urge surfing, and recalling the negative outcomes of
gambling)
M5: Unhelpful thinking • Review common thinking errors related to gambling (or “gambling traps”)
• Psychoeducation about games of chance
• Identify how misperceptions about gambling odds impact one’s inner dialogue or thoughts
• Introduce the thought record as a way to see associations between situations, automatic thoughts, behaviours, and
gambling consequences
• Help foster identification of “gambling traps” and strategies to challenge them
M6: Dealing with slips • Define a “slip” versus a full-blown relapse
• Introduce ways to cope with slip in gambling
• Introduce relapse prevention planning
M7: Preserve your
success
• Identify “early warning signs” for slip/relapse
• Create personalized relapse prevention plan
• Discuss ways to cope with relapse
• Identify top five coping strategies for preventing gambling
• How to know if more treatment is needed (with corresponding recommendations)
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have a dedicated DMC. We do not intend to conduct
any interim analyses nor have any stopping guidelines
been established. Safety monitoring and reporting ad-
verse events will be the responsibility of the trial princi-
pal investigator, Dr. Keough. At present, there are no
plans to externally audit the trial.
Ethical considerations
The intervention will be designed to adhere to the eth-
ical principles of the Declaration of Helsinki. Ethics ap-
proval will be obtained from the REB at the University
of Manitoba and York University before study initiation.
Participant data will be kept confidential. To achieve
this, we will be using arbitrary identifiers (e.g. numerical
IDs) for participants. These identifiers will be used to
link data over time, but the data set will not contain per-
sonal information. We will keep a master list of partici-
pant contact information in a separate password-
protected master list. We are also aware of the increased
risks associated with recruiting adults with clinically ele-
vated gambling problems, considering the high rates of
comorbid mental health problems with disordered gam-
bling [86]. We would expect higher base rates of suicid-
ality and self-harming behaviours in these individuals
relative to those without these substance use and behav-
ioural addiction concerns. Accordingly, we will have
safeguards to minimize risk of harm. Adults who report
significant suicide ideation and/or plans during screen-
ing will be given a recommendation to visit their local
medical professional (GP or hospital) for support. They
will also be given access to the integrated intervention,
but their data will not be analysed. We will also be mon-
itoring changes in suicidality at each assessment and will
direct participants to emergency services if needed. Par-
ticipants will also have full-time access to a list of mental
health services listed on the intervention website, includ-
ing community resources, public and private psycholo-
gists, hospitals, and helplines. Dr. Keough will be
available to speak with participants if serious issues arise
(i.e. increase in suicidal ideation) and will make sure a
safe course of action is followed. The reporting of harms
is the responsibility of Dr. Keough as outlined in the ap-
proved ethics documents. If a participant feels uncom-
fortable at any time during treatment, they are free to
withdraw and cease their involvement in the trial. For
ethical reasons, people with clinically elevated AUD/
SUD symptoms will be provided with access to the inte-
grated treatment instead of being denied access should
they require the intervention as a resource for their
problem gambling and/or smoking behaviours. However,
their data will not be included in the study. Finally, par-
ticipants in the gambling only control condition will be
given access to the active integrated treatment after the
final assessment (6 months) should they wish. They will
receive all elements of the integrated arm, including
NRT.
Implications of the proposed pilot study
High rates of problem gambling and tobacco use in
North America demonstrate a clear need for more men-
tal health services in the country around this crucial
issue. Some provinces and states also have significant
rural spread, meaning that several communities are dis-
persed throughout the province with little access to
major city centres. This poses a huge challenge for pro-
viding equal access to mental health care services for all
North Americans. In fact, statistics suggest that people
living in remote communities are at a significant disad-
vantage [7, 8]. They seem to be struggling most with ad-
diction and related problems, but have limited access to
treatment facilities. Thus, the proposed study has the
potential to substantially improve the health and well-
being of adults living across the continent. Furthermore,
if supported, the proposed intervention would be a cost-
effective method (relative to traditional in-person treat-
ments) of improving gambling addiction care delivery to
North Americans. Online interventions have the poten-
tial to save the government thousands of dollars via the
reduced burden on the health care system. We plan to
disseminate the results of the pilot study widely, which
will include giving talks at Manitoba Blue Cross/AFM
locations across the province, at major hospitals and
universities in Manitoba, and at public institutions (e.g.
libraries). We will publish results in open-access jour-
nals, so that the public and policymakers in North
America can learn about (and use) the intervention.
Trial status
To ensure transparency, the current study has been reg-
istered on the clinicaltrials.gov website (Clinicaltrials.gov
ID NCT03614884). Any protocol modifications will be
updated on clinicaltrials.gov and on the consent form lo-
cated on the online intervention website.
Protocol version number: NCT03614884.
Date trial was registered: August 3, 2018.
Date recruitment began: May 2, 2019.
Last update posted: September 25, 2019.
Estimated date when recruitment will be completed:
December 31, 2020.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s13063-020-04867-1.
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